SCID Model Market, By Model (Mouse, Pigs and Other), By Treatment (Stem Cell Therapy, Gene Therapy, and Enzyme Therapy), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI478121 | Publish Date: May 2024 | No. of Pages: 180

Global SCID Model Market Overview

SCID Models Market garnered a revenue of USD 43.50 Million in the year 2019 globally and has been foreseen to yield USD 61.95 Million by the year 2027 at a compound annual growth (CAGR) of 4.6% over the forecast period.

A lot of research investigations are being conducted with mice, pigs, and other animals in order to produce a new SCID model. Initially, liver mice models were created by implanting human liver cells or hepatic cancer cells into basic immune-deficient mice. The results, however, were inconsistent and unreliable. In addition, researchers are investigating the development of severe combined immunodeficient (SCID) pig models for translational cancer modelling. Several severe combined immunodeficient (SCID) pig models have been developed or genetically created in the previous decade. SCID pigs with NK cells but lacking in T and B cells, or defective in NK, T, and B cells for research investigations, have mutations in the ARTEMIS, IL2RG, or RAG1/2 genes, or combinations thereof.

Global SCID Model Market Dynamics

Cancer Research will drive the growth of the Market

In the United States and around the world, cancer has a significant impact on society. In the United States, a projected 1,806,590 new cases of cancer will be identified in 2020, with 606,520 people dying from the disease. Breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukaemia, pancreatic cancer, thyroid cancer, and liver cancer are the most common cancers (listed in descending order by estimated new cases in 2020). In 2020, prostate, lung, and colorectal cancers are expected to account for 43 percent of all malignancies diagnosed in men. Breast, lung, and colorectal cancers are the three most common cancers in women, accounting for roughly half of all new cancer diagnoses in women by 2020.

Global SCID Model Market Segmentation

SCID Model Market is segmented based on model, treatment and region.

On the basis of Model, the SCID Model Market is segmented into Mouse, Pig and Others. Based on Treatment, the target market is segmented into Stem Cell Therapy, Gene Therapy, and Enzyme Therapy.

Regional Insights:

On region the SCID Model Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The generation of animal models for uncommon diseases such as osteoarthritis and cardiomyopathy by pharmaceutical companies in partnership with other institutions is driving the growth of the North American SCID models market. Humanized mouse models are in high demand across North America, because to rising demand for tailored medication. The possible applications of SCID models in North America include genetic flaw rectification, disease treatment, and disease prevention. CRISPR-Cas9 has made it possible to create transgenic animal models. It enables genome editing to be done at a lower cost and in less time, as well as the generation of animals with more extensive genetic alterations. Animal models that have been genetically modified to mimic human diseases are crucial in the pathological research of a variety of conditions. In compared to traditional gene-targeting technologies, the introduction of the CRISPR system has facilitated the quick and cost-effective manufacture of animal models.

SCID Model Market Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Model- Mouse, Pigs and Others

By Treatment– Stem Cell Therapy, Gene Therapy, and Enzyme Therapy

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the SCID Model Market report based on Model, Treatment and region.

SCID Model Market Segmentation

SCID Model Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East & Africa

Global SCID Model Market Key Players

The key players profiled in SCID Model report include Charles River Laboratories International, Inc, Envigo, Eurofins Scientific SE, GenOway S.A., Hera BioLabs (Transposagen Biopharmaceuticals), JSR Corporation (Crown Bioscience Inc.), Ozgene Pty Ltd., PerkinElmer, Inc. (Horizon Discovery Group plc.), Taconic Biosciences, and The Jackson Laboratory.

Global SCID Model Market Company Profile

  • Charles River Laboratories International, Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Envigo
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eurofins Scientific SE
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • The Jackson Laboratory
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hera BioLabs (Transposagen Biopharmaceuticals)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • JSR Corporation (Crown Bioscience Inc.)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Ozgene Pty Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • PerkinElmer, Inc. (Horizon Discovery Group plc.)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

Global SCID Model Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Preview
    • Executive Summary
    • Key Findings—Global Outlook for SCID Model Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Model
      • Market Snippet, By Treatment
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Market Segmentation, By Model, 2020 – 2030, (US$ Mn)
    • Overview         
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Mouse
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Pigs
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Market Segmentation, By Treatment, 2020 – 2030, (US$ Mn)
    • Overview                                                 
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Stem Cell Therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Gene Therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Enzyme Therapy
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Model, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Treatment, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  9. Company Profiles
  • Charles River Laboratories International, Inc
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Envigo
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eurofins Scientific SE
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • The Jackson Laboratory
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Hera BioLabs (Transposagen Biopharmaceuticals)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • JSR Corporation (Crown Bioscience Inc.)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Ozgene Pty Ltd.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • PerkinElmer, Inc. (Horizon Discovery Group plc.)
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

Model Market is segmented based on model, treatment and region.

Increase in Cancer Research is major factor driving the market.

During the forecast period, North America is expected to dominate the market.

The key players profiled in SCID Model report include Charles River Laboratories International, Inc, Envigo, Eurofins Scientific SE, GenOway S.A., Hera BioLabs (Transposagen Biopharmaceuticals), JSR Corporation (Crown Bioscience Inc.), Ozgene Pty Ltd., PerkinElmer, Inc. (Horizon Discovery Group plc.), Taconic Biosciences, and The Jackson Laboratory.